Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00743587
Other study ID # A9001383
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 2008
Est. completion date March 2009

Study information

Verified date November 2018
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if the measurement of pressure pain thresholds, in patients suffering osteoarthritis of the thumb, can be used to assess the activity of potential analgesic agents after a single dose. The study will use agents known to give pain relief in osteoarthritis as positive controls. These agents are: tramadol, naproxen and oxycodone.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date March 2009
Est. primary completion date March 2009
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- The clinical diagnosis of osteoarthritis of the hand, of at least 6 months duration.

- Pain around one of the thumb joints due to osteoarthritis. The patient must report the average pain in this joint, in the week prior to screening, as at least 5 on an 11-point numerical pain rating scale at the time of screening.

- The patient must demonstrate pressure pain at a thumb joint by reporting a pressure pain threshold lower than 300 kPa.

Exclusion Criteria:

- Pregnant (as judged by a urine pregnancy test) or lactating female.

- Other severe pain which may impair the assessment of the pain due to osteoarthritis.

- Skin condition over the thumb joint, which will be used for pain threshold testing, that could interfere with the assessment of pain thresholds.

- Known hypersensitivity to oxycodone, NSAIDS or tramadol.

- Patients in whom NSAIDS, oxycodone or tramadol are contraindicated, or patients taking any concurrent medications which are contraindicated with any of the study medications .

- An estimated renal clearance of less than 30 mL/min based on the Cockcroft Gault equation.

- Use of prohibited medications as listed below, in the absence of appropriate washout periods:

- Oral or intramuscular corticosteroids within 4 weeks prior to screening.

- Monoamine oxidase inhibitors within 2 weeks of screening.

- Analgesic agents, other than aspirin, or acetaminophen within 1 week prior to screening. (Aspirin use less than or equal to 325 mg per day for cardiovascular prophylaxis is permitted)

- Acetaminophen up to 4 g/day may be used, provided it is not used in the 24 hours prior to any assessment of pain thresholds.

- Intra-articular steroid injections into the study joint within 12 weeks, or to any other joint within 4 weeks, prior to screening.

- History of chronic constipation, or of any condition which, in the opinion of the investigator, may put the patient at increased risk of respiratory depression.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
Oxycodone
Oral, 1 x 20mg controlled-release tablets
Tramadol
Oral, 2 x 50mg immediate release capsules
Naproxen
Oral, 1 x 500mg enteric-coated

Locations

Country Name City State
Belgium Pfizer Investigational Site Bruxelles

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pressure pain threshold - area under the curve 0 to 4 hours
Secondary Pressure pain threshold - at specific time points 0 to 12 hours
Secondary Present pain intensities - at specific time points 0 to 12 hours